TTM
−$58.88M
YoY change
-28.3%
5Y CAGR
—
Peak year (2023)
$4.91M
Cumulative EBITDA
−$572.30M
EBITDA history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: −$57.39M
EBITDA growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: -28.3%
EBITDA history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | −$57.39M | -28.3% | +$22.59M | ||
| 2024 | −$79.98M | -1728.9% | −$84.89M | ||
| 2023 | $4.91M | -103.1% | +$161.95M | ||
| 2022 | −$157.04M | +24.9% | −$31.29M | ||
| 2021 | −$125.75M | +111.9% | −$66.42M | ||
| 2020 | −$59.33M | +292.8% | −$44.23M | ||
| 2019 | −$15.11M | -8.7% | +$1.45M | ||
| 2018 | −$16.55M | +139.4% | −$9.64M | ||
| 2017 | −$6.92M | -0.1% | +$8.00K | ||
| 2016 | −$6.92M | -56.8% | +$9.11M | ||
| 2015 | −$16.03M | -6.2% | +$1.06M | ||
| 2014 | −$17.09M | +37865.1% | −$17.04M | ||
| 2013 | −$45.02K | +285.6% | −$33.34K | ||
| 2012 | −$11.68K | — | — |
- 2025−$57.39M-28.3%
- 2024−$79.98M-1728.9%
- 2023$4.91M-103.1%
- 2022−$157.04M+24.9%
- 2021−$125.75M+111.9%
- 2020−$59.33M+292.8%
- 2019−$15.11M-8.7%
- 2018−$16.55M+139.4%
- 2017−$6.92M-0.1%
- 2016−$6.92M-56.8%
- 2015−$16.03M-6.2%
- 2014−$17.09M+37865.1%
- 2013−$45.02K+285.6%
- 2012−$11.68K—
EBITDA values are taken from Relmada Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's current EBITDA (TTM) is −$58.88M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual EBITDA for Relmada Therapeutics (RLMD) came in at −$57.39M – declined 28.3% year-over-year.
Relmada Therapeutics EBITDA peaked at $4.91M in 2023; the latest annual figure is −$57.39M in 2025 (1268.7% below peak).
The highest annual EBITDA of $4.91M was reported in 2023. The lowest in the available history was −$157.04M in 2022.
Relmada Therapeutics EBITDA by Year
Relmada Therapeutics EBITDA 2025: −$57.39M
In 2025, Relmada Therapeutics reported EBITDA of −$57.39M, declined 28.3% below 2024.
Relmada Therapeutics EBITDA 2024: −$79.98M
Relmada Therapeutics EBITDA in 2024 was −$79.98M, plunged 1728.9% below 2023.
Relmada Therapeutics EBITDA 2023: $4.91M
2023's EBITDA for Relmada Therapeutics came in at $4.91M, plunged 103.1% below 2022. This figure represents the highest annual value in the available history.
Relmada Therapeutics EBITDA 2022: −$157.04M
Relmada Therapeutics posted EBITDA of −$157.04M in 2022, grew 24.9% from 2021. This figure represents the lowest annual value in the available history.
Relmada Therapeutics EBITDA 2021: −$125.75M
Relmada Therapeutics EBITDA in 2021 was −$125.75M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by EBITDA
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation